» Articles » PMID: 37324533

Study to Assess Content Validity and Interrater and Intrarater Reliability of the Inclusion Body Myositis Functional Rating Scale

Overview
Date 2023 Jun 16
PMID 37324533
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Sporadic inclusion body myositis (IBM) is a rare, muscle-wasting disease that negatively affects health-related quality of life. Although a measure that has been developed to assess the impact of IBM, the IBM Functional Rating Scale (IBMFRS) has limited evidence of content validity or reliability, and what constitutes a meaningful change threshold; this study was conducted to address these gaps.

Methods: Adult patients with a clinical diagnosis of IBM from the United Kingdom and disease area expert health care professionals from the United States and United Kingdom took part in this study. This study consisted of 5 stages including phone interviews (physicians), face-to-face interviews (patients), face-to-face ratings, phone ratings, and ratings of videos using the IBMFRS.

Results: The IBMFRS adequately captures all core functional impacts of IBM, which was corroborated by both patient participants and physicians when debriefing the measure. Physicians and patient participants all thought any change on the measure would be meaningful change for a patient, either improvement or worsening. The quantitative analysis demonstrated good interrater reliability for face-to-face ratings (intraclass correlation coefficient [ICC] >0.7) and for video ratings (ICC >0.9). Intrarater reliability was excellent for face-to-face and video ratings (ICC >0.9). Equivalence between the modes of administration, face-to-face vs phone, was also excellent (ICC >0.9).

Discussion: The IBMFRS is content valid in assessing the key functional impacts of IBM, and any change would be meaningful. It is reliable both within and across raters, and there is equivalence between different modes of administration (face-to-face vs phone).

Citing Articles

Efficacy and safety of pharmacological treatments in inclusion body myositis: a systematic review.

Santos E, Farisogullari B, Yapp N, Townsley H, Sousa P, Machado P RMD Open. 2025; 11(1).

PMID: 39843353 PMC: 11759215. DOI: 10.1136/rmdopen-2024-005176.


Testing the Validity and Reliability of a Standardized Virtual Examination for Concussion.

Jack A, Digney H, Bell C, Grossman S, McPherson J, Saleem G Neurol Clin Pract. 2024; 14(5):e200328.

PMID: 38895642 PMC: 11182663. DOI: 10.1212/CPJ.0000000000200328.


Exploring challenges in the management and treatment of inclusion body myositis.

Skolka M, Naddaf E Curr Opin Rheumatol. 2023; 35(6):404-413.

PMID: 37503813 PMC: 10552844. DOI: 10.1097/BOR.0000000000000958.

References
1.
Rose M . 188th ENMC International Workshop: Inclusion Body Myositis, 2-4 December 2011, Naarden, The Netherlands. Neuromuscul Disord. 2013; 23(12):1044-55. DOI: 10.1016/j.nmd.2013.08.007. View

2.
Machado P, Brady S, Hanna M . Update in inclusion body myositis. Curr Opin Rheumatol. 2013; 25(6):763-71. PMC: 4196838. DOI: 10.1097/01.bor.0000434671.77891.9a. View

3.
Qin S, Nelson L, McLeod L, Eremenco S, Coons S . Assessing test-retest reliability of patient-reported outcome measures using intraclass correlation coefficients: recommendations for selecting and documenting the analytical formula. Qual Life Res. 2018; 28(4):1029-1033. PMC: 6439259. DOI: 10.1007/s11136-018-2076-0. View

4.
Dimachkie M, Barohn R . Inclusion body myositis. Neurol Clin. 2014; 32(3):629-46, vii. PMC: 4115580. DOI: 10.1016/j.ncl.2014.04.001. View

5.
Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A . Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005; 8(2):94-104. DOI: 10.1111/j.1524-4733.2005.04054.x. View